Search

Your search keyword '"Juliusson, Gunnar"' showing total 7 results
Start Over Author "Juliusson, Gunnar" Journal blood advances
7 results on '"Juliusson, Gunnar"'

2. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

3. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML

Author

von Palffy, Sofia, primary, Thorsson, Hanna, additional, Peña-Martínez, Pablo, additional, PUENTE-MONCADA, NOELIA, additional, Sandén, Carl, additional, Blom, Anna M, additional, Henningsson, Rasmus, additional, Juliusson, Gunnar, additional, King, Ben C, additional, Landberg, Niklas, additional, Lazarevic, Vladimir Lj, additional, Orsmark-Pietras, Christina, additional, Rissler, Marianne, additional, Rissler, Vendela, additional, Agerstam, Helena, additional, Järås, Marcus, additional, Lilljebjörn, Henrik, additional, and Fioretos, Thoas, additional

Published
2022
Full Text
View/download PDF

5. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Author

Juliusson, Gunnar, primary, Jädersten, Martin, primary, Deneberg, Stefan, primary, Lehmann, Sören, primary, Möllgård, Lars, primary, Wennström, Lovisa, primary, Antunovic, Petar, primary, Cammenga, Jörg, primary, Lorenz, Fryderyk, primary, Ölander, Emma, primary, Lazarevic, Vladimir Lj, primary, and Höglund, Martin, primary

Published
2020
Full Text
View/download PDF

6. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells

Author

Eriksson, Mia, primary, Peña-Martínez, Pablo, additional, Ramakrishnan, Ramprasad, additional, Chapellier, Marion, additional, Högberg, Carl, additional, Glowacki, Gabriella, additional, Orsmark-Pietras, Christina, additional, Velasco-Hernández, Talía, additional, Lazarević, Vladimir Lj, additional, Juliusson, Gunnar, additional, Cammenga, Jörg, additional, Mulloy, James C., additional, Richter, Johan, additional, Fioretos, Thoas, additional, Ebert, Benjamin L., additional, and Järås, Marcus, additional

Published
2017
Full Text
View/download PDF

7. The prognostic impact of FLT3-ITD and NPM1mutation in adult AML is age-dependent in the population-based setting

Author

Juliusson, Gunnar, Jädersten, Martin, Deneberg, Stefan, Lehmann, Sören, Möllgård, Lars, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Lorenz, Fryderyk, Ölander, Emma, Lazarevic, Vladimir Lj, and Höglund, Martin

Abstract

In acute myeloid leukemia (AML) FLT3internal tandem duplication (ITD) and nucleophosmin 1 (NPM1) mutations provide prognostic information with clinical relevance through choice of treatment, but the effect of age and sex on these molecular markers has not been evaluated. The Swedish AML Registry contains data on FLT3-ITD and NPM1mutations dating to 2007, and 1570 adult patients younger than 75 years, excluding acute promyelocytic leukemia, had molecular results reported. Females more often had FLT3ITDand/or NPM1mut(FLT3ITD: female, 29%; male, 22% [P= .0015]; NPM1mut: female, 36%; male, 27% [P= .0001]), and more males were double negative (female, 53%; male, 64%; P< .0001). Patients with FLT3ITDwere younger than those without (59 vs 62 years; P= .023), in contrast to patients with NPM1mut(62 vs 60 years; P= .059). Interestingly, their prognostic effect had a strong dependence on age: FLT3ITDindicated poor survival in younger patients (<60 years; P= .00003), but had no effect in older patients (60-74 years; P= .5), whereas NPM1mutindicated better survival in older patients (P= .00002), but not in younger patients (P= .95). In FLT3ITD/NPM1mutpatients, the survival was less dependent on age than in the other molecular subsets. These findings are likely to have clinical relevance for risk grouping, study design, and choice of therapy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results